Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6160468 | Kidney International | 2015 | 9 Pages |
Abstract
Monoclonal immunoglobulin deposition disease (MIDD) is a rare complication of plasma cell disorders, defined by linear Congo red-negative deposits of monoclonal light chain, heavy chain, or both along basement membranes. While renal involvement is prominent, treatment strategies, such as the impact of novel anti-myeloma agents, remain poorly defined. Here we retrospectively studied 49 patients with MIDD who received a median of 4.5 cycles of intravenous bortezomib plus dexamethasone. Of these, 25 received no additional treatment, 18 also received cyclophosphamide, while 6 also received thalidomide or lenalidomide. The hematological diagnoses identified 38 patients with monoclonal gammopathy of renal significance, 10 with symptomatic multiple myeloma, and 1 with Waldenstrom macroglobulinemia. The overall hematologic response rate, based on the difference between involved and uninvolved serum-free light chains (dFLCs), was 91%. After median follow-up of 54 months, 5 patients died and 10 had reached end-stage renal disease. Renal response was achieved in 26 patients, with a 35% increase in median eGFR and an 86% decrease in median 24-h proteinuria. Predictive factors were pre-treatment eGFR over 30Â ml/min per 1.73Â m2 and posttreatment dFLC under 40Â mg/l; the latter was the sole predictive factor of renal response by multivariable analysis. Thus, bortezomib-based therapy is a promising treatment strategy in MIDD, mainly when used early in the disease course. dFLC response is a favorable prognostic factor for renal survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Camille Cohen, Bruno Royer, Vincent Javaugue, Raphael Szalat, Khalil El Karoui, Alexis Caulier, Bertrand Knebelmann, Arnaud Jaccard, Sylvie Chevret, Guy Touchard, Jean-Paul Fermand, Bertrand Arnulf, Frank Bridoux,